Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data

Vivani Medical, Inc.

2025-Q1 EPS reported -$0.11

FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.
LIBERATE-1 (NPM-115 exenatide) fully enrolled; top-line data expected mid-2025.
NPM-139 (semaglutide) preclinical data positive, once-yearly dosing potential.
Closed $8.25M equity financing on March 27, 2025 to fund into Q2 2026.
Plans to spin off Cortigent subsidiary as independent public company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.